GlassScriptPhysician profile
Thomas Michael Fitzgerald
NPI 1841231834
$1,940.97
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,652 · 2020: $125 · 2022: $164.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $1,247.73 | 2019 | |
| Abbott Laboratories | $243.01 | 2019-2022 | |
| Treace Medical Concepts, INC. | $125.00 | 2020 | |
| Zimmer Biomet Holdings, INC. | $109.30 | 2019 | |
| Innovation Technologies INC | $106.00 | 2019 | |
| Stryker Corporation | $38.74 | 2019 | |
| Bioventus LLC | $17.02 | 2019 | |
| Derma Sciences, INC. | $16.60 | 2019 | |
| Merck Sharp & Dohme LLC | $12.67 | 2019 | |
| Paragon 28, INC. | $12.60 | 2019 | |
| Smith+Nephew, INC. | $12.30 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Fitzgerald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.